الفهرس 
Hepatitis C virusOnly 14 pages are availabe for public view
 |  | from | 114 |  |  |
| | | from | 114 | | |
Abstract
Egypt has the highest prevalence of antibodies to hepatitis C virus
(HCV) in the world, estimated nationally at 14.7%. There are over
500,000 new infected persons per year by hepatitis C virus.
More than 90 % of Egyptian patients are infected with genotype IV.
Liver mortality in Egypt reaches 40,000 per year, making 10% of
total mortality, and comes second after heart diseases.
The goal of antiviral therapy is to cure hepatitis C via a sustained
elimination of the virus. Importantly, long-term benefits of sustained
virological response (SVR) are the reduction of HCV-related
hepatocellular carcinoma and overall mortality.
The development of new direct acting anti-viral for the treatment of
chronic hepatitis C patients give us and the patients a new hope for
cure from that disease and its complication.
Our study which was conducted in the national hepatology and
tropical medicine research institute (NHTMRI) on 200 Egyptian
patients who were eligible to be treated with Sofosbuvir, Interferon
and ribavirin.
All the included patients received Pegylated Interferon 180 mcg SC
injection once / week, Weight-based RBV (1000 mg [<75 kg] to 1200 mg [≥75 kg]) oral capsule divided every 8 hours and sofosbuvir (400
mg) oral capsule every 24 hours for 12 weeks.
The enrolled patients were divided into two groups, 100 naïve
patients, and 100 patients who experienced IFN therapy before (43
patients were relapser after INF treatment, 34 patients were non
responder to INF treatment while other 23 patients were breakthrough
during INF treatment)
We started with 204 patients, 4 patient were excluded due to
discontinuation of the therapy, 2 of them were naïve, one stopped the
therapy after development of ascites and the other stopped the therapy
due to severe thrombocytopenia.
The other 2 patients one of them was from relapser group and the
other one was from the non-responder group and stopped treatment
after development of hepatocellular carcinoma.
128 patients were males while 72 patients were females.
Regarding the degree of fibrosis which had been assessed by either
FIB4, fibroscan or liver biopsy. there were 74 patients had fibrosis
(F3) , 42 patients were in stage (F3-F4) and 84 patients were in the
stage (F4) of fibrosis .
176 patients of the evaluated patients were Child A (88 %), 23
patients Child B (11.5 %) and only one patient was Child C (.5 %)The mean age of the study group was 50.4 ±11 years, the mean BMI
of the study group was 28,2 ± 3.6 kg/m2 ,the mean number of years
from discovering to starting the triple therapy was 7.02 ±4.8 , the
mean AFP of the study 13.5 ± 8 ng /ml , the mean HCV PCR of the
study group before starting treatment 4455971.67± 18775223.9.